Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BrE-3 ricin A-chain
- Development stage
- Preclinical
- Lead developer
- The Institute of Cancer Research
- Modality
- Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
BrE-3 ricin A-chain is an experimental **immunotoxin** created by the chemical conjugation of the monoclonal antibody BrE-3 (which targets the polypeptide core of the MUC1 mucin gene product) to the **A-chain of ricin**, a potent ribosome-inactivating protein. The immunotoxin is designed to selectively target and kill human small-cell lung cancer (SCLC) cells expressing MUC1 mucin by delivering ricin A-chain's catalytic activity directly to the tumor cell. The mechanism of cytotoxicity relies on ricin A-chain’s **rRNA N-glycosidase activity**, which inactivates ribosomes in the target cells, thereby irreversibly inhibiting cellular protein synthesis and inducing cell death. Preclinical studies demonstrated high potency and selectivity for SCLC cell lines in vitro.
- Other names
- anti-mucin immunotoxin BrE-3-ricin A-chain
02
Targets
28S rRNA (28S ribosomal RNA)SRL (28S rRNA sarcin-ricin loop)MUC1 (Mucin-1 Antigen)
Beyond the preview
Go deeper on BrE-3 ricin A-chain.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BrE-3 ricin A-chain.